Related Experiment Video
Updated: Jul 6, 2025
13:08
Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay
Published on: September 9, 2012
19.0K
Factor XI and coagulation. Factor XI inhibitors - antithrombotic perspectives
Ana-Maria Vlădăreanu1, Adrian Roşca2
11"Carol Davila" University of Medicine and Pharmacy, Department of Hematology, Emergency University Hospital of Bucharest, Romania.
Summary
Factor XI (FXI) plays a dual role in blood clotting, contributing to both bleeding and thrombosis. Inhibiting FXI shows promise for preventing thrombotic events.
Area of Science:
- Hematology
- Vascular Biology
- Pharmacology
Background:
- Factor XI (FXI) is a key zymogen in the coagulation cascade.
- FXI activation by FXII, thrombin, or autoactivation contributes to prothrombotic and antifibrinolytic effects.
- Severe FXI deficiency causes hemophilia C, characterized by bleeding, while elevated FXI levels increase thrombotic risk.
Purpose of the Study:
- To investigate the therapeutic potential of FXI inhibitors for preventing thrombotic events.
- To evaluate the efficacy and safety of FXI inhibitors in clinical trials.
Main Methods:
- Review of current literature on Factor XI's role in coagulation.
- Analysis of data from Phase II clinical trials of FXI inhibitors.
Main Results:
- Lowering serum FXI levels is a validated target for thrombotic event prevention.
- FXI inhibitors demonstrated promising efficacy and safety profiles in Phase II trials.
- FXI inhibitors represent a novel class of anticoagulants with potential for broad clinical applications.
Conclusions:
- Factor XI is a significant target for anticoagulant therapy.
- FXI inhibitors offer a new therapeutic strategy for preventing thrombosis.
- Emerging FXI inhibitors may expand anticoagulant treatment options beyond current standards.
Related Concept Videos
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
702
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
702
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.2K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.2K
01:20Extrinsic and Intrinsic Pathways of Hemostasis
7.8K
Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
7.8K
01:09Coagulation
6.7K
The coagulation phase is a critical part of the body's process to prevent blood loss following injury to blood vessels. It involves chemical reactions that form a clot to seal the injured area. The clotting process begins shortly after injury, within 15-20 seconds for severe damage and 1-2 minutes for minor injuries.
During the coagulation phase, clotting factors, or procoagulants, play a vital role in initiating and progressing the coagulation cascade. This cascade is a series of reactions...
During the coagulation phase, clotting factors, or procoagulants, play a vital role in initiating and progressing the coagulation cascade. This cascade is a series of reactions...
6.7K
01:16Clot Retraction and Fibrinolysis
6.0K
After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
6.0K
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
526
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
526